EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Strata Skin Sciences's Enterprise Value is €9.07 Mil.
Strata Skin Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.72 Mil. Therefore, Strata Skin Sciences's EV-to-FCF for today is -2.44.
The historical rank and industry rank for Strata Skin Sciences's EV-to-FCF or its related term are showing as below:
FRA:E2O'
s EV-to-FCF Range Over the Past 10 Years
Min: -1232.65 Med: -6.21 Max: 99999999.99
Current: -2.14
During the past 13 years, the highest EV-to-FCF of Strata Skin Sciences was 99999999.99. The lowest was -1232.65. And the median was -6.21.
FRA:E2O's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.19
vs FRA:E2O: -2.14
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Strata Skin Sciences's PE Ratio (TTM) for today is calculated as:
Strata Skin Sciences's share price for today is €3.76.
Strata Skin Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.363.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Strata Skin Sciences EV-to-FCF Related Terms
Strata Skin Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Strata Skin Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's EV-to-FCF falls into.
Strata Skin Sciences's current Enterprise Value is €9.07 Mil.
Strata Skin Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences (FRA:E2O) has a EV-to-FCF of -2.44 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Strata Skin Sciences' EV-to-FCF too high?
Strata Skin Sciences' current EV-to-FCF is -2.44. Based on the distribution chart, Strata Skin Sciences ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' EV-to-FCF compare to ODYY and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #999999 out of 414 companies for EV-to-FCF. This places Strata Skin Sciences in the lower half of its industry. The industry median EV-to-FCF is 23.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.19, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current EV-to-FCF is -2.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current EV-to-FCF of -2.44. The stock's GF Value™ is €59.29, compared to a current price of €3.76 — trading 93.7% below its estimated fair value. The current EV-to-FCF is -2.44. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current EV-to-FCF is -2.44 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 93.7% below its estimated GF Value™ of €59.29.
Key valuation signals for FRA:E2O:
EV-to-FCF: -2.44
GF Value™: €59.29 vs. price of €3.76 (93.7% below fair value)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
